- Overview
- Properties
- Related Genes
- Pathways
- Related Drugs
- Related Diseases
- Datasets
- Downloads/LinkOuts
Overview
| Generic Names: | Dehydrocortisone; PRD; Prednisona [INN-Spanish]; Prednisonum [INN-Latin] |
|---|---|
| IUPAC Name: | (8S,9S,10R,13S,14S,17R)-17-hydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,9,12,14,15,16-octahydrocyclopenta[a]phenanthrene-3,11-dione |
| Trade Names: | Adasone; Ancortone; Apo-prednisone; Betapar; Bicortone; Cartancyl; Colisone; Cortan; Cortancyl; Cortidelt; Cotone; Dacorten; Dacortin; Decortancyl; Decortin; Decortisyl; Dekortin; Delcortin; Dellacort; Dellacort A; Delta Cortelan; Delta E; Delta-cortelan; Delta-cortisone; Delta-cortone; Delta-dome; Deltacortene; Deltacortisone; Deltacortone; Deltasone; Deltison; Deltisona; Deltisone; Deltra; Di-Adreson; Diadreson; Econosone; Encorton; Encortone; Enkorton; Fernisone; Fiasone; Hostacortin; In-Sone; Incocortyl; Juvason; Lisacort; Me-Korti; Metacortandracin; Meticorten; Nisona; Nizon; Novoprednisone; Nurison; Orasone; Origen Prednisone; Panafcort; Panasol; Paracort; Parmenison; Pehacort; Precort; Predeltin; Prednicen-M; Prednicorm; Prednicort; Prednicot; Prednidib; Prednilonga; Prednison; Prednisone Intensol; Prednitone; Prednizon; Prednovister; Presone; Pronison; Rectodelt; Retrocortine; Servisone; Sone; Sterapred; Supercortil; Ultracorten; Ultracortene; Winpred; Wojtab; Zenadrid |
| Brand Mixtures: | Cortab (Biotin + Chlorpheniramine Maleate + D-Pantothenic Acid + Inositol + Nicotinic Acid + Prednisone + Pyridoxine Hydrochloride + Thiamine Mononitrate + Vitamin a + Vitamin B2 + Vitamin D + Vitamin E (Dl-Alpha Tocopheryl Acetate)); Metreton Tab (Chlorpheniramine Maleate + Prednisone + Vitamin C); Predniderm Tab (Inositol + Pheniramine Maleate + Phosphatidyl Choline + Prednisone + Vitamin a + Vitamin D2 + Vitamin E); Sterolin Liq (Biotin + Fatty Acids Unsaturated + Inositol + Nicotinic Acid + Pheniramine Maleate + Phosphatidyl Choline + Prednisone + Vitamin a Palmitate + Vitamin B2 + Vitamin D2 + Vitamin E) |
| PharmGKB Accession Id: | PA451100 |
Description
A synthetic anti-inflammatory glucocorticoid derived from cortisone. It is biologically inert and converted to prednisolone in the liver. [PubChem]
Indication
For the treatment of drug-induced allergic reactions, perennial or seasonal allergic rhinitis, serum sickness, giant cell arteritis acute rheumatic or nonrheumatic carditis, systemic dermatomyositis, systemic lupus erythematosus, atopic dermatitis, contact dermatitis, exfoliative dermatitis, bullous dermatitis herpetiformis, severe seborrheic dermatitis, severe (Stevens-Johnson syndrome) erythema multiforme, mycosis fungoides, pemphigus, severe psoriasis, acute adrenocortical insufficiency, Addison's disease, secondary adrenocortical insufficiency, congenital adrenal hyperplasia, hypercalcemia associated with neoplasms, nonsuppurative thyroiditis, ulceratice colitis, Crohn's disease, acquired hemolytic anemia, congenital hypoplastic anemia, erythroblastopenia, adult secondary thrombocytopenia, adult idiopathic thrombocytopenia purpura, acute or subacute bursitis, epicondylitis, acute nonspecific tenosynovitis, acute or chronic lymphocytic leukemia, Hodgkin's or non-Hodgkin's lynphomas, Waldenstrom's macroglobulinemia, primary brain tumors (adjunct), nephrotic syndrome, tuberculous meningitis, multiple sclerosis, myasthenia gravis. cerebral edema, chorioretinitis, diffuse posterior choroiditis, aleergic conjunctivitis, Herpes zoster ophthalmicus, anterior segment inflammation, iridocyclitis, iritis, keratitis, optoc neuritis, sympathetic ophthalmia, corneal marginal allergic ulcers, symptomatic sarcoidosis, Loeffler's syndrome not manageable by other means, berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy and aspiration pneumonitis.
ATC Therapeutic Categories
- A07EA:Corticosteroids acting locally
- H02AB:Glucocorticoids
Pharmacology and Interactions
Mechanism Of Action
Prednisone is a glucocorticoid agonist. It is first metabolized in the liver to its active form, prednisolone. Prednisolone crosses cell membranes and binds with high affinity to specific cytoplasmic receptors. The result includes inhibition of leukocyte infiltration at the site of inflammation, interference in the function of mediators of inflammatory response, suppression of humoral immune responses, and reduction in edema or scar tissue. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.
Pharmacology
Prednisone, the most commonly-prescribed corticosteroid, is used to treat allograft rejection, asthma, systemic lupus erythematosus, and many other inflammatory states. Prednisone has very little mineralocorticoid activity.
Food Interactions
Avoid alcohol. Avoid taking with grapefruit juice. Take with food to reduce irritation.
Absorption, Distribution, Metabolism, Elimination & Toxicity
Biotransformation
Hepatic.
Protein Binding
Extensively bound to plasma proteins.
Absorption
Readily absorbed from the gastrointestinal tract.
Half Life
2 to 3 hours
Chemical Properties
Chemical Formula:
C21H26O5
SMILES Code:
C[C@]12CC(=O)[C@H]3[C@H]([C@@H]1CC[C@@]2(C(=O)CO)O)CCC4=CC(=O)C=C[C@]34C
(Format: OpenEye Isomeric)
Molecular Weight ( average / monoisotopic )
358.4281 / 358.178
Curated Information
The following genes are in curated knowledge about this drug.
| Gene | Relationship | Evidence | |
|---|---|---|---|
|
|
ABCB1 |
|
Publications |
|
|
CREBBP |
|
Pathways |
|
|
CYP3A4 |
|
Publications |
|
|
CYP3A5 |
|
Publications |
|
|
FKBP4 |
|
Pathways |
|
|
GSTM1 |
|
Publications |
|
|
GSTP1 |
|
Publications |
|
|
GSTT1 |
|
Publications |
|
|
HSP90AA1 |
|
Pathways |
|
|
HSPA4 |
|
Pathways |
|
|
IL10 |
|
Publications |
|
|
MSH6 |
|
Publications |
|
|
MTHFR |
|
Publications |
|
|
NCOA3 |
|
Pathways |
|
|
NR3C1 |
|
Publications, Pathways |
|
|
SAA1 |
|
Publications |
|
|
SERPINA6 |
|
Pathways |
|
|
SLC19A1 |
|
Publications |
|
|
ST13 |
|
Pathways |
|
|
TBP |
|
Pathways |
|
|
TPMT |
|
Publications |
|
|
TYMS |
|
Publications |
|
|
UGT1A1 |
|
Publications |
|
|
VDR |
|
Publications |
Non-Curated Information
A list of non-curated publications that mention this drug along with other genes is available.
Metabolizing Enzymes
Drug Targets
PharmGKB Curated Pathways
- Glucocorticoid and Inflammatory genes Pathway (PD)
- Glucocorticoid and Inflammatory genes Pathway (Regulation)
BioCarta Pathways†
- chromatin remodeling by hswi/snf atp-dependent complexes - (BioCarta via Pathway Interaction Database)
- corticosteroids and cardioprotection - (BioCarta via Pathway Interaction Database)
Non-Curated Information
A list of non-curated publications that mention this drug along with other drugs is available.
Drug Interactions
| acenocoumarol | The corticosteroid alters the anticoagulant effect |
| ambenonium | The corticosteroid decreases the effect of anticholinesterases |
| amobarbital | The barbiturate decreases the effect of the corticosteroid |
| anisindione | The corticosteroid alters the anticoagulant effect |
| aprobarbital | The barbiturate decreases the effect of the corticosteroid |
| aspirin | The corticosteroid decreases the effect of salicylates |
| bismuth subsalicylate | The corticosteroid decreases the effect of salicylates |
| butabarbital | The barbiturate decreases the effect of the corticosteroid |
| butalbital | The barbiturate decreases the effect of the corticosteroid |
| butethal | The barbiturate decreases the effect of the corticosteroid |
| chlorotrianisene | The estrogenic agent increases the effect of corticosteroid |
| clomifene | The estrogenic agent increases the effect of corticosteroid |
| conjugated estrogens | The estrogenic agent increases the effect of corticosteroid |
| dicumarol | The corticosteroid alters the anticoagulant effect |
| diethylstilbestrol | The estrogenic agent increases the effect of corticosteroid |
| dihydroquinidine barbiturate | The barbiturate decreases the effect of the corticosteroid |
| edrophonium | The corticosteroid decreases the effect of anticholinesterases |
| estradiol | The estrogenic agent increases the effect of corticosteroid |
| estriol | The estrogenic agent increases the effect of corticosteroid |
| estrone | The estrogenic agent increases the effect of corticosteroid |
| estropipate | The estrogenic agent increases the effect of corticosteroid |
| ethinyl estradiol | The estrogenic agent increases the effect of corticosteroid |
| ethotoin | The enzyme inducer decreases the effect of the corticosteroid |
| fosphenytoin | The enzyme inducer decreases the effect of the corticosteroid |
| heptabarbital | The barbiturate decreases the effect of the corticosteroid |
| hexobarbital | The barbiturate decreases the effect of the corticosteroid |
| itraconazole | The imidazole increases the effect and toxicity of the corticosteroid |
| ketoconazole | The imidazole increases the effect and toxicity of the corticosteroid |
| mephenytoin | The enzyme inducer decreases the effect of the corticosteroid |
| mestranol | The estrogenic agent increases the effect of corticosteroid |
| methohexital | The barbiturate decreases the effect of the corticosteroid |
| methylphenobarbital | The barbiturate decreases the effect of the corticosteroid |
| midodrine | Increased arterial pressure |
| neostigmine | The corticosteroid decreases the effect of anticholinesterases |
| pentobarbital | The barbiturate decreases the effect of the corticosteroid |
| phenobarbital | The barbiturate decreases the effect of the corticosteroid |
| phenytoin | The enzyme inducer decreases the effect of the corticosteroid |
| primidone | The barbiturate decreases the effect of the corticosteroid |
| pyridostigmine | The corticosteroid decreases the effect of anticholinesterases |
| quinestrol | The estrogenic agent increases the effect of corticosteroid |
| quinidine barbiturate | The barbiturate decreases the effect of the corticosteroid |
| rifampin | The enzyme inducer decreases the effect of the corticosteroid |
| salicylate-magnesium | The corticosteroid decreases the effect of salicylates |
| salicylate-sodium | The corticosteroid decreases the effect of salicylates |
| salsalate | The corticosteroid decreases the effect of salicylates |
| secobarbital | The barbiturate decreases the effect of the corticosteroid |
| talbutal | The barbiturate decreases the effect of the corticosteroid |
| trisalicylate-choline | The corticosteroid decreases the effect of salicylates |
| warfarin | The corticosteroid alters the anticoagulant effect |
Curated Information
The following diseases are in curated knowledge about this drug.
| Disease | Relationship | Evidence | |
|---|---|---|---|
|
|
Arthritis, Rheumatoid |
|
Publications |
|
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma |
|
Publications |
Non-Curated Information
A list of non-curated publications that mention this drug along with other diseases is available.
Curated Phenotype Datasets
These datasets are sorted alphabetically by title.
- Pharmacogenetic Risk Factors for Osteonecrosis of the Hip Among Children With Leukemia




- CO
Submitted by Mary Relling, PharmD involving ABCB1, CYP3A4, CYP3A5, GSTM1, GSTP1, GSTT1, MTHFR, NR3C1, SLC19A1, TPMT, TYMS, UGT1A1, VDR, dexamethasone, methotrexate, prednisone, , Osteonecrosis and Precursor Cell Lymphoblastic Leukemia-Lymphoma - Tacrolimus dosing and Steroid Weaning in pediatric heart transplant patients




- CO
- PK
Submitted by Burckart GJ involving ABCB1, CYP3A4, CYP3A5, glucocorticoids, prednisone, tacrolimus, and Organ Transplantation
Additional Datasets
These datasets are minimally curated and are sorted alphabetically by title.
- Genetic predictors of glucocorticoid-induced hypertension in children with acute lymphoblastic leukemia
- Genome-wide copy number profiling reveals molecular evolution from diagnosis to relapse in childhood acute lymphoblastic leukemia
- Osteonecrosis in Children with Acute Lymphoblastic Leukemia: A Report from the Children's Oncology Group
- Pharmacogenetics of Minimal Residual Disease Response in Children with B-Precursor Acute Lymphoblastic Leukemia (ALL): A Report from the Children's Oncology Group
- Physicochemical determinants of human renal clearance
- The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease
Downloads
You must sign in before you can download data.
LinkOuts
Common Searches
Search PubMed
Search Medline Plus
Search PubChem
Search CTD
Non-Curated Publications
A list of non-curated publications that mention this drug is available.
